New York Senate Bill S07839

New York 2025-2026 Regular Session

• Introduced: 5/9/25
• Refer: 5/9/25

Caption

Prohibits the sale of medical adhesives and bandages containing perfluoroalkyl and polyfluoroalkyl substances; provides penalties for violations.

Impact

If enacted, S07839 would have a significant effect on manufacturers and retailers of medical adhesives and bandages, compelling them to ensure that their products do not contain prohibited substances. The bill imposes civil penalties for violations and emphasizes the importance of compliance, requiring sellers to possess a certificate of compliance from manufacturers. This step is aimed at encouraging manufacturers to re-evaluate the chemicals used in their products and transition to safer alternatives, thereby promoting a more sustainable and health-conscious market.

Summary

Bill S07839 aims to prohibit the sale of medical adhesives and bandages that contain perfluoroalkyl and polyfluoroalkyl substances (PFAS), which are known to pose significant environmental and health risks. The legislation seeks to amend the environmental conservation law, specifically by introducing a new prohibition against the intentional addition of PFAS in these medical products. By doing so, the bill intends to protect public health and limit the distribution of harmful chemicals in products designed for medical use.

Contention

While proponents of S07839 argue that it is a necessary measure to safeguard public health from the dangers posed by PFAS, there may be contention regarding the economic implications for manufacturers required to reformulate their products. Critics could argue that such regulations might lead to increased costs and potential supply disruptions, which could affect the availability of medical supplies. Additionally, the implementation timeline, with the law coming into effect on December 31, 2026, raises questions about the preparedness of the industry to comply with these new standards.